Brief: Hansoh Pharmaceutical Says Third Biologics License Application Of Xinyue (Inebilizumab Injection) Accepted By NMPA
30/05/2025 18:31
May 30 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK: THIRD BIOLOGICS LICENSE APPLICATION OF XINYUE (INEBILIZUMAB INJECTION) WAS ACCEPTED BY NMPA Further company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion